- In April 2023, Vericel Corporation, a leader in advanced cell therapies, announced the expansion of its MACI (autologous cultured chondrocytes on porcine collagen membrane) production capacity in the U.S. to meet growing demand for cartilage repair procedures. This strategic investment reinforces Vericel’s commitment to supporting regenerative treatment adoption and improving patient outcomes for knee cartilage injuries. The expansion is expected to enhance supply chain efficiency and accelerate delivery timelines, further strengthening the company’s presence in the cartilage regeneration space
- In March 2023, Smith & Nephew launched its REGENETEN Bioinductive Implant in additional global markets following strong clinical adoption in the U.S. Initially used in rotator cuff repair, the platform is being explored for broader cartilage regeneration applications. The device’s minimally invasive nature and ability to support tissue regrowth make it a promising tool in cartilage healing, aligning with the industry’s shift toward biologic, less invasive solutions for joint preservation
- In March 2023, BioTissue Holdings Inc. reported successful outcomes from a clinical study evaluating its amniotic suspension allograft in treating knee osteoarthritis. The study revealed substantial improvements in joint function and pain reduction, positioning BioTissue’s solution as a viable alternative to invasive joint replacement. The findings support the expanding role of biologic allografts in cartilage regeneration, especially for patients seeking non-surgical therapeutic options
- In February 2023, CO.DON AG, a German biotech company specializing in autologous cartilage cell therapy, received continued post-market approval for its chondrosphere product in Europe. The approval confirms the long-term safety and efficacy of the treatment and enables broader adoption across European orthopedic centers. CO.DON’s work exemplifies the growing traction of cell-based therapies in regulated markets and their expanding use in both early and advanced cartilage degeneration cases
In January 2023, Orthocell Ltd., an Australian regenerative medicine company, announced positive interim results from its CelGro scaffold clinical trial for cartilage repair. The bioresorbable scaffold demonstrated strong integration and cartilage-such as tissue regeneration in patients with chondral defects. These results underscore the importance of scaffold technology in providing structural support for cell attachment and growth, highlighting its role in the next generation of cartilage regeneration therapies
